Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5]. Core Insights - The company reported total revenue of $5.3 billion for 2025, a year-on-year increase of 40%, and achieved a GAAP net profit of $287 million, marking a return to profitability [2]. - The sales of the core product, Zebutinib, continued to grow rapidly, with Q4 2025 sales reaching $1.15 billion, a 39% increase year-on-year [3]. - The company provided guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion, with GAAP operating expenses of $4.7 billion to $4.9 billion and a gross margin in the high 80% range [3]. Financial Performance - The company’s revenue is expected to grow from $5.34 billion in 2025 to $6.43 billion in 2026, reflecting a growth rate of 20.27% [10]. - The net profit forecast for 2026 is adjusted to $685 million, with a significant growth rate of 138.6% compared to 2025 [10]. - The diluted earnings per share (EPS) is projected to be $0.44 in 2026, up from $0.19 in 2025 [10]. Research and Development Pipeline - The company is advancing its R&D pipeline, with several key milestones expected in 2026, including interim analysis for Zebutinib in MCL and potential approvals for other products [4]. - The company anticipates data releases for various clinical trials in the first half of 2026, which could serve as catalysts for future growth [4].
百济神州（06160）：业绩符合预期，早研管线步入收获期